[Form 4] Mind Medicine (MindMed) Inc. Insider Trading Activity

Rhea-AI Filing Summary

Definium Therapeutics, Inc. granted its Chief Financial Officer, Brandi Roberts, an award of 150,000 restricted stock units (RSUs). Each RSU represents the right to receive one common share.

The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026, as long as Roberts continues providing service on each vesting date. The award was reported as a direct, no-cost acquisition, with 150,000 common shares beneficially owned following the transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Roberts Brandi

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	150,000	$0.00	--

Holdings After Transaction: Common Shares — 150,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Roberts Brandi

(Last) (First) (Middle)

C/O DEFINIUM THERAPEUTICS, INC.

ONE WORLD TRADE CENTER, SUITE 8500

(Street)

NEW YORK NY 10007

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Definium Therapeutics, Inc. [ DFTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/03/2026		A		150,000(1)	A	$0.00	150,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date.

	/s/ Mark Sullivan, Attorney-in-Fact for Brandi Roberts	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Definium Therapeutics (DFTX) report for its CFO?

Definium Therapeutics reported that CFO Brandi Roberts received 150,000 restricted stock units. Each RSU is a contingent right to one common share, granted at a reported price of $0.00 per share as part of her compensation package.

How many Definium Therapeutics (DFTX) RSUs were granted to the CFO?

The CFO was granted 150,000 restricted stock units of Definium Therapeutics common shares. These RSUs increase her reported beneficial ownership to 150,000 shares following the transaction, aligning her compensation more closely with the company’s equity performance over time.

When do the Definium Therapeutics (DFTX) CFO’s RSUs start vesting?

The RSUs start vesting on June 1, 2026. Vesting then continues in 16 equal quarterly installments, so portions of the 150,000 units become deliverable every quarter, contingent on the CFO’s continued service with Definium Therapeutics.

Over what period will the DFTX CFO’s 150,000 RSUs fully vest?

The 150,000 RSUs vest in 16 equal quarterly installments beginning June 1, 2026. This structure spreads vesting over four years, with each quarter’s installment conditioned on the CFO remaining in continuous service through that vesting date.

What does the $0.00 price mean for the DFTX CFO’s RSU grant?

The $0.00 price indicates the RSUs were granted as compensation, not purchased for cash. Each RSU converts into one common share at no cost to the CFO upon vesting, subject to the continued service requirement at each quarterly vesting date.